2,614 Shares in BioNTech SE (NASDAQ:BNTX) Acquired by Alyeska Investment Group L.P.

Alyeska Investment Group L.P. acquired a new stake in BioNTech SE (NASDAQ:BNTX) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 2,614 shares of the company’s stock, valued at approximately $298,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BNTX. FMR LLC increased its stake in shares of BioNTech by 22.2% during the 4th quarter. FMR LLC now owns 7,701,476 shares of the company’s stock worth $877,583,000 after purchasing an additional 1,401,547 shares in the last quarter. Capital International Investors increased its position in BioNTech by 38.6% during the fourth quarter. Capital International Investors now owns 1,415,566 shares of the company’s stock worth $161,304,000 after buying an additional 394,434 shares in the last quarter. abrdn plc raised its holdings in shares of BioNTech by 70.7% in the fourth quarter. abrdn plc now owns 385,668 shares of the company’s stock worth $43,947,000 after acquiring an additional 159,676 shares during the last quarter. Franklin Resources Inc. lifted its position in shares of BioNTech by 3,942.1% in the fourth quarter. Franklin Resources Inc. now owns 136,786 shares of the company’s stock valued at $15,587,000 after acquiring an additional 133,402 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in shares of BioNTech during the fourth quarter valued at $14,091,000. 15.52% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

BNTX has been the topic of a number of recent research reports. HC Wainwright reduced their target price on shares of BioNTech from $150.00 to $145.00 and set a “buy” rating on the stock in a report on Tuesday, April 1st. Citigroup reissued a “buy” rating and set a $140.00 price target (down previously from $145.00) on shares of BioNTech in a research note on Tuesday. Canaccord Genuity Group reissued a “buy” rating and issued a $171.44 target price on shares of BioNTech in a research report on Tuesday, March 11th. BMO Capital Markets increased their price target on shares of BioNTech from $130.00 to $143.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 11th. Finally, Morgan Stanley lowered their price objective on shares of BioNTech from $140.00 to $132.00 and set an “overweight” rating for the company in a research note on Tuesday. Three equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $142.73.

BioNTech Stock Performance

BioNTech stock opened at $94.74 on Wednesday. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The stock has a 50 day moving average of $99.87 and a 200-day moving average of $109.87. The stock has a market cap of $22.73 billion, a P/E ratio of -45.11 and a beta of 1.35. BioNTech SE has a 52 week low of $76.53 and a 52 week high of $131.49.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.24 billion. During the same period last year, the business earned $1.90 EPS. The firm’s revenue for the quarter was down 19.5% compared to the same quarter last year. On average, analysts expect that BioNTech SE will post -3.88 EPS for the current fiscal year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.